What's wrong with chemoprevention of prostate cancer?

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Prostate-specific antigen (PSA) testing was introduced with the aim of reducing prostate cancer mortality.
• However, evidence for PSA's mortality benefit is unclear, while overtreatment is a significant concern.
• This has led to interest in mitigating the harms associated with the PSA testing system.

Purpose of the Study:

• To evaluate the role of finasteride and dutasteride in prostate cancer prevention.
• To assess the rationale for using these drugs in light of the PSA testing system's limitations.
• To examine the potential mortality benefits and risks associated with finasteride and dutasteride.

Main Methods:

• Review of existing evidence on PSA testing and its impact on prostate cancer mortality and overtreatment.
• Analysis of studies on finasteride and dutasteride regarding their effects on prostate cancer incidence and diagnosis.
• Critical assessment of the rationale for using these drugs for prevention within the context of the PSA system.

Main Results:

• Finasteride and dutasteride reduce prostate cancer incidence and the risk of diagnosis.
• The rationale for using these drugs for prevention is linked to the flaws within the PSA testing system.
• The mortality benefits of finasteride and dutasteride are speculative, similar to PSA, and they introduce new risks.

Conclusions:

• The utility of finasteride and dutasteride for prostate cancer prevention is questionable due to their dependence on a flawed PSA system.
• The speculative mortality benefits and additional risks associated with these drugs warrant careful consideration.
• Reducing the human costs of the PSA system requires a critical re-evaluation of current prevention strategies.